News
NICE backs first ophthalmic bevacizumab for NHS use
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Europe’s Largest Industry-Led & Dedicated Gathering for mRNA...
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
Category :
Views & Analysis
/
